Saturday 17 October 2026 Export ELMD’s income statement to Excel — free account

Electromed, Inc.

Electromed, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $73.8 million, up 15.3% from fiscal 2025. In the quarter to June 2026, revenue grew 11.6%, EPS grew 57.7% and free cash flow fell 25.2%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

27.42 0.61 −2.18%

Follow ELMD

Alert me

Market cap: $232.3M
P/E: 20.0×
Fwd P/E: 25.5×
Dividend yield: —
F-score: 8/9
Altman Z: 20.30
Beneish M: −2.20
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.20

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	1	2	—	—	—	—

Insider Ownership 17.01%

Capital & Financial Ratios $m

Market Cap 232.29

Revenue 73.78

Net Income 11.30

Free Cash Flow 8.37

Net Debt (20.45)

Current Ratio 4.69

Debt/Equity 0.00

P/E ratio 20.01

Fwd P/E 25.50

P/S ratio 3.07

P/B ratio 4.20

Past 5Y EPS Growth 36.94%

This Y EPS Growth 11.92%

Next Y EPS Growth 16.15%

Next Y revenue growth 12.71%

Next 5Y EPS Growth 17.15%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 10.91%

10-year low 10-year high

P/S against its own 10 years 81.98%

10-year low 10-year high

P/B against its own 10 years 82.16%

10-year low 10-year high

EV/Sales against its own 10 years 81.50%

10-year low 10-year high

EV/FCF against its own 10 years 45.98%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	7	16	15	20
Receivables	24	23	25	31
Inventory	4	4	3	4
Other	0	1	1	1
	38	44	45	57

	2023	2024	2025	2026
Payables	1	1	3	3
ST’ Debt	—	—	—	—
Other	3	2	3	4
	8	8	10	12

Compound Annual Growth %

	10y	5y	3y
Sales	12.37%	15.59%	15.35%
Cash Flow	16.13%	25.72%	94.43%
Earnings	17.71%	36.76%	52.83%
Book Value	12.68%	10.74%	12.74%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	17	19	19	19	74
’25	15	16	16	17	64
’24	12	14	14	15	55
’23	11	12	12	14	48
’22	10	10	10	11	42
’21	8	9	9	9	36

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	0	3	3	3	10
’25	2	3	2	4	11
’24	0	3	1	4	9
’23	(2)	1	1	1	1
’22	(1)	0	0	(1)	(1)
’21	1	1	1	1	3

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	0	2	3	3	8
’25	2	3	2	4	11
’24	0	3	1	4	9
’23	(2)	1	0	1	0
’22	(1)	0	0	(1)	(2)
’21	1	1	1	1	3

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	0.25	0.32	0.35	0.39	1.30
’25	0.16	0.22	0.21	0.25	0.85
’24	0.02	0.19	0.17	0.20	0.58
’23	0.01	0.11	0.12	0.12	0.36
’22	0.05	0.10	0.07	0.04	0.26
’21	0.06	0.13	0.03	0.04	0.27

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	3.68	4.60	4.75	6.92	8.98	8.75	8.80	9.81	17.73	23.01	Analyst estimates 2027–2029 Powerpack
	High	7.96	7.33	10.99	19.73	13.85	13.46	13.84	31.31	35.56	47.40
People
People	Employees	115	132	119	120	132	156	170	174	180	197
	Revenue/emp, $m	0.22	0.21	0.26	0.27	0.27	0.27	0.28	0.31	0.36	0.37
Income, $m
Income, $m	Revenue	26	28	31	32	36	42	48	55	64	74
	Gross margin, %	79.53	76.92	76.19	77.61	76.36	75.47	75.98	76.26	78.08	78.54
	EBT	4	3	3	5	3	3	4	7	10	14
	EBT margin, %	13.61	9.65	9.33	16.13	8.86	7.19	8.50	12.86	16.07	19.46
	Net income	2	2	2	4	2	2	3	5	8	11
	Depreciation	1	1	1	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	3.17	3.45	3.77	3.86	4.17	4.92	5.68	6.39	7.57	8.93
	Earnings	0.27	0.23	0.24	0.50	0.28	0.27	0.37	0.60	0.89	1.37
	Cash flow	0.15	0.30	0.31	0.50	0.36	(0.08)	0.16	1.06	1.35	1.17
	Capex	(0.08)	(0.07)	(0.17)	(0.12)	(0.05)	(0.18)	(0.20)	(0.05)	(0.04)	(0.16)
	Free cash flow	0.06	0.23	0.14	0.38	0.31	(0.26)	(0.05)	1.01	1.31	1.01
	Book value	2.33	2.75	3.10	3.60	3.78	4.03	4.45	5.20	5.11	6.53
	Shares, m	8	8	8	8	9	8	8	9	8	8
Valuation, ×
Valuation, ×	P/E	20.48	23.48	22.04	31.41	40.32	34.43	28.18	23.58	24.99	30.88
	P/S	1.75	1.57	1.40	3.98	2.70	1.96	1.89	2.21	2.90	4.74
	P/B	2.37	1.96	1.71	4.28	2.98	2.39	2.41	2.72	4.30	6.48
	EV/Sales	1.58	1.38	1.19	3.70	2.40	1.79	1.76	1.94	2.68	4.48
	EV/FCF	80.86	20.88	30.95	37.28	32.69	(33.76)	(210.50)	12.25	15.49	39.49
Cash, $m
Cash, $m	Operating cash flow	1	2	3	4	3	(1)	1	9	11	10
	Capex	(1)	(1)	(1)	(1)	0	(2)	(2)	0	0	(1)
	Free cash flow	1	2	1	3	3	(2)	0	9	11	8
Balance, $m
Balance, $m	Working capital	16	18	21	25	27	27	30	36	35	45
	Total debt	1	1	0	0	0	0	0	—	—	—
	Net debt	(4)	(6)	(8)	(10)	(12)	(8)	(7)	(16)	(15)	(20)
	Shareholders’ equity	19	23	26	30	32	34	38	45	43	54
Returns, %
Returns, %	ROA	10.22	7.26	6.97	13.28	6.71	5.87	7.26	10.51	14.22	18.82
	ROIC	15.24	10.44	9.85	16.12	9.56	7.14	8.27	14.45	21.62	25.87
	ROE	12.59	8.79	8.20	14.86	7.54	6.92	8.81	12.53	17.18	23.26

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
QSI Quantum-Si Incorporated	$286.7M	— (loss-making)	— (loss-making)	−41.79% (below 0%: shrinking)	n/m	+9.75% (above 0%: growing)	50.00%	(7,450.29%)	Compare
INFU InfuSystems Holdings, Inc.	$277.2M	31.7×	21.7×	+2.59% (above 0%: growing)	+33.33% (above 0%: growing)	−66.54% (below 0%: shrinking)	57.98%	11.24%	Compare
TMCI Treace Medical Concepts, Inc.	$267.9M	— (loss-making)	— (loss-making)	−4.24% (below 0%: shrinking)	n/m	+11.74% (above 0%: growing)	78.47%	(32.96%)	Compare
CATX Perspective Therapeutics, Inc.	$267.1M	— (loss-making)	— (loss-making)	−72.07% (below 0%: shrinking)	n/m	−66.09% (below 0%: shrinking)	100.00%	(36,120.99%)	Compare
LAB Standard BioTools Inc.	$258.5M	2.9×	— (loss-making)	−7.62% (below 0%: shrinking)	n/m	+52.76% (above 0%: growing)	52.40%	(126.28%)	Compare
TLSI TriSalus Life Sciences, Inc.	$240.1M	— (loss-making)	— (loss-making)	+1.73% (above 0%: growing)	n/m	−41.29% (below 0%: shrinking)	86.78%	(86.03%)	Compare
ELMD Electromed, Inc.	$232.3M	20.0×	25.5×	+11.64% (above 0%: growing)	+57.69% (above 0%: growing)	−25.15% (below 0%: shrinking)	78.71%	19.70%
PROF Profound Medical	$230.5M	— (loss-making)	— (loss-making)	+12.30% (above 0%: growing)	n/m	+17.51% (above 0%: growing)	78.41%	(445.67%)	Compare
RXST RxSight, Inc.	$194.2M	— (loss-making)	— (loss-making)	+0.31% (above 0%: growing)	n/m	−94.39% (below 0%: shrinking)	76.72%	(40.81%)	Compare
Median of peers	$262.8M	—	—	−1.96%	—	−15.77%	77.57%	(106.15%)

All 149 Medical Devices stocks →

Electromed, Inc. (ELMD) key facts

Strength: Electromed, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $73.8 million, up 15.3% from fiscal 2025.
Electromed, Inc. (ELMD) is a Medical Devices company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, ELMD traded at $27.42, a market capitalization of $232.3 million.
Return on equity was 23.3% and debt-to-equity 0.00.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 20.30 (safe zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.